| Literature DB >> 35621959 |
Concetta Maria Messina1, Rosaria Arena1, Simona Manuguerra1, Laura La Barbera2, Eleonora Curcuraci1, Giuseppe Renda1, Andrea Santulli1,2.
Abstract
The valorization of side streams from fishery and aquaculture value-chains is a valuable solution to address one of the challenges of the circular economy: turning wastes into profit. Side streams produced after filleting of sea cage fattened bluefin tuna (Thunnus thynnus) were analyzed for proximate composition and fatty acid profile to evaluate the possibility of producing tuna oil (TO) as a valuable source of ω-3 polyunsaturated fatty acids (PUFA) and testing its bioactivity in vitro. Ethyl esters of total fatty acids (TFA), obtained from TO, were pre-enriched by urea complexation (PUFA-Ue) and then enriched by short path distillation (SPD) up to almost 85% of the PUFA fraction (PUFA-SPe). The bioactivity of TFA, PUFA-SPe, and ethyl esters of depleted PUFA (PUFA-SPd) were tested in vitro, through analysis of lipid metabolism genes, in gilthead sea bream (Sparus aurata) fibroblast cell line (SAF-1) exposed to oils. TFA and PUFA-SPd upregulated transcription factors (pparβ and pparγ) and lipid metabolism-related genes (D6D, fas, fabp, fatp1, and cd36), indicating the promotion of adipogenesis. PUFA-SPe treated cells were similar to control. PUFA-SPe extracted from farmed bluefin tuna side streams could be utilized in fish feed formulations to prevent excessive fat deposition, contributing to improving both the sustainability of aquaculture and the quality of its products.Entities:
Keywords: SAF-1 cell line; adipogenesis; biomarkers; lipid metabolism; side streams; tuna fish oils; ω-3 fatty acids
Mesh:
Substances:
Year: 2022 PMID: 35621959 PMCID: PMC9147267 DOI: 10.3390/md20050309
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Proximate composition (mean ± SD) (g/100 g) of total side stream minced from wild (BFT-W), farmed (BFT-F < 60 kg; BFT-F > 200 kg) bluefin tuna, and wild yellowfin tuna (YFT-W).
| Moisture | Ash | Total Lipid | Protein | |
|---|---|---|---|---|
| BFT-W | 62.1 ± 2.0 c | 4.8 ± 0.4 a | 19.6 ± 1.5 b | 13.3 ± 3.4 a |
| BFT-F > 200 kg | 46.8 ± 1.8 a | 5.52 ± 2.1 a | 32.1 ± 2.1 c | 14.2 ± 1.8 a |
| BFT-F < 60 kg | 57.1 ± 1.1 b | 4.25 ± 0.5 a | 22.5 ± 1.2 b | 19.2 ± 2.4 b |
| YFT-W | 61.0 ± 1.5 c | 6.4 ± 1.1 b | 10.8 ± 0.8 a | 20.5 ± 3.2 c |
Means in the same column with different superscript letters are significantly different (p < 0.05). The data are reported as mean ± standard deviation, n = 12.
FA profile (relative percentage with respect to total FAs) of total pooled side streams from BFT-F > 200 kg.
| FA | BFT-F |
|---|---|
| 14:0 | 5.79 ± 0.18 |
| 16:0 | 20.16 ± 0.96 |
| 16:1ω-7 | 6.84 ± 0.45 |
| 16:2ω-4 | 1.03 ± 0.02 |
| 16:3ω-4 | 0.56 ± 0.19 |
| 18:0 | 4.43 ± 0.13 |
| 18:1ω-9 | 15.71 ± 0.61 |
| 18:1ω-7 | 6.78 ± 0.27 |
| 18:2ω-6 | 1.22 ± 0.03 |
| 18:3ω-3 | 6.03 ± 0.59 |
| 20:1ω-9 | 2.77 ± 0.09 |
| 20:4ω-6 | 0.54 ± 0.01 |
| 20:4ω-3 | 0.29 ± 0.01 |
| 20:5ω-3 (EPA) | 9.93 ± 0.36 |
| 22:1ω-11 | 4.30 ± 0.57 |
| 22:6ω-3 (DHA) | 13.64 ± 0.56 |
| SFA | 30.38 ± 0.71 |
| MUFA | 36.40 ± 1.36 |
| PUFA | 33.22 ± 1.72 |
| Totω-3 | 29.89 ± 1.49 |
| Totω-6 | 1.75 ± 0.03 |
| EPA + DHA | 23.57 ± 0.92 |
| PI | 1.17 ± 0.09 |
| AI | 0.62 ± 0.01 |
| AT | 0.24 ± 0.01 |
The data are reported as mean ± standard deviation, n = 12. SFA Saturated fatty acids; MUFA Monounsaturated fatty acids; PUFA Polyunsaturated fatty acids; PI polyene index; AI atherogenicity index; TI thrombogenicity index.
TO quality determined by: Peroxide Value: PV; ρ-Anisidine: ρ-AV; Thiobarbituric acid reactive substances: TBARS; Total Oxidation Value: TOTOX; Acid value and Free Fatty Acid percentage: FFA%. Commercial Cod liver oil (CO) was used as control.
| TO | CO | |
|---|---|---|
| PV (meq O2/kg) | 2.96 ± 0.55 b | 2.10 ± 0.53 a |
| ρ-AV | 12.93 ± 1.53 b | 4.96 ± 0.89 a |
| TBARS (MDA µg/g) | 11.81 ± 2.45 b | 5.51 ± 0.81 a |
| TOTOX | 20.80 ± 0.88 b | 10.83 ± 0.24 a |
| Acid value (FFA%) | 2.25 ± 0.32 b | 0.50 ± 0.04 a |
Different superscript letters in the same raw indicate significant differences (p < 0.05). The data are reported as mean ± standard deviation (n = 12).
FA profile (relative percentage with respect to total FAs) of total methyl esters in Tuna Oil (TO), total FA ethyl esters (TFA), and samples pre enriched by urea complexation (PUFA-Ue).
| FA | TO | TFA | PUFA-Ue |
|---|---|---|---|
| 14:0 | 6.82 ± 0.11 b | 6.99 ± 0.10 b | 4.37 ± 0.18 a |
| 16:0 | 21.15 ± 0.31 c | 19.38 ± 0.22 b | 9.21 ± 0.23 a |
| 16:1ω-7 | 7.27 ± 0.09 c | 6.24 ± 0.09 b | 4.09 ± 0.06 a |
| 16:2ω-4 | 1.53 ± 0.19 b | 1.34 ± 0.11 b | 0.27 ± 0.03 a |
| 16:3ω-4 | 0.84 ± 0.13 b | 0.79 ± 0.03 b | 0.41 ± 0.08 a |
| 18:0 | 3.75 ± 0.22 b | 2.85 ± 0.12 a | 3.73 ± 0.05 b |
| 18:1ω-9 | 15.42 ± 0.4 c | 13.80 ± 0.3 b | 8.52 ± 0.35 a |
| 18:1ω-7 | 6.66 ± 0.13 b | 6.96 ± 0.31 b | 3.67 ± 0.28 a |
| 18:2ω-6 | 1.21 ± 0.02 a | 3.25 ± 0.08 b | 5.29 ± 0.09 c |
| 18:3ω-6 | 0.44 ± 0.29 a | 0.99 ± 0.25 a | 2.50 ± 0.12 b |
| 18:3ω-3 | 0.92 ± 0.09 a | 0.89 ± 0.15 a | 8.47 ± 0.1 b |
| 20:1ω-9 | 3.00 ± 0.42 a | 3.04 ± 0.18 a | 3.66 ± 0.34 a |
| 20:4ω-6 | 0.59 ± 0.04 a | 0.34 ± 0.21 a | 2.38 ± 0.22 b |
| 20:4ω-3 | 0.44 ± 0.08 a | 0.20 ± 0.13 a | 1.78 ± 0.07 b |
| 20:5ω-3 | 9.73 ± 0.35 a | 10.26 ± 0.05 a | 10.96 ± 0.03 b |
| 22:1ω-11 | 4.84 ± 0.35 a | 5.02 ± 0.32 a | 5.06 ± 0.18 a |
| 22:1ω-9 | 0.16 ± 0.05 a | 0.14 ± 0.03 a | 0.16 ± 0.04 a |
| 22:4ω-6 | 0.41 ± 0.10 a | 1.37 ± 0.29 b | 1.53 ± 0.09 c |
| 22:5ω-3 | 1.21 ± 0.05 a | 1.25 ± 0.09 a | 1.43 ± 0.012 b |
| 22:6ω-3 | 13.60 ± 0.08 a | 14.90 ± 0.16 b | 22.50 ± 0.45 c |
| SFA | 31.72 ± 0.90 a | 29.23 ± 1.21 a | 17.31 ± 1.51 b |
| MUFA | 37.36 ± 1.88 c | 35.19 ± 1.18 b | 25.16 ± 1.18 a |
| PUFA | 30.92 ± 1.08 a | 35.58 ± 1.19 b | 57.53 ± 1.35 c |
| Totω-3 | 25.90 ± 0.65 a | 27.50 ± 0.95 b | 45.14 ± 1.75 c |
| Totω-6 | 2.20 ± 0.38 a | 4.96 ± 0.34 b | 9.20 ± 0.86 c |
| EPA + DHA | 23.33 ± 0.98 a | 25.15 ± 0.75 b | 33.46 ± 1.02 c |
| PI | 1.10 ± 0.02 a | 1.30 ± 0.03 b | 3.63 ± 0.25 c |
| AI | 0.71 ± 0.09 b | 0.67 ± 0.09 b | 0.32 ± 0.02 a |
| TI | 0.29 ± 0.04 b | 0.27 ± 0.02 b | 0.11 ± 0.01 a |
Different superscript letters in the same row indicate significant differences (p < 0.05). The data are reported as mean ± standard deviation, n = 12.
FA profile (relative percentage with respect to total FAs) of the oils, pre enriched by urea (PUFA-Ue), enriched in PUFA (PUFA-SPe), and exhausted in fatty acid ethyl esters (PUFA-SPe), obtained by short path distillation (SPD) at 160 °C.
| FA | PUFA-Ue | PUFA-SPe | PUFA-SPd |
|---|---|---|---|
| 14:0 | 4.37 ± 0.18 b | 0.86 ± 0.03 a | 6.39 ± 0.49 c |
| 16:0 | 9.21 ± 0.23 b | 2.23 ± 0.06 a | 14.38 ± 0.53 c |
| 16:1ω-7 | 4.09 ± 0.06 b | 0.99 ± 0.01 a | 5.99 ± 0.12 c |
| 16:2ω-4 | 0.27 ± 0.03 b | 0.22 ± 0.01 b | 0.07 ± 0.03 a |
| 16:3ω-4 | 0.41 ± 0.08 b | 0.26 ± 0.00 a | 0.80 ± 0.12 c |
| 18:0 | 3.73 ± 0.05 b | 1.64 ± 0.06 a | 4.37 ± 0.24 c |
| 18:1ω-9 | 8.52 ± 0.35 b | 2.39 ± 0.19 a | 14.58 ± 0.11 c |
| 18:1ω-7 | 3.67 ± 0.28 b | 0.95 ± 0.03 a | 4.52 ± 0.14 c |
| 18:2ω-6 | 5.29 ± 0.09 b | 3.14 ± 0.06 a | 5.29 ± 0.67 a |
| 18:3ω-6 | 2.50 ± 0.12 b | 1.48 ± 0.16 a | 2.86 ± 0.23 b |
| 18:3ω-3 | 8.47 ± 0.10 b | 8.33 ± 0.10 b | 4.99 ± 0.28 a |
| 20:1ω-9 | 3.66 ± 0.34 b | 1.29 ± 0.06 a | 5.70 ± 0.27 a |
| 20:4ω-6 | 2.38 ± 0.22 b | 2.63 ± 0.13 b | 0.48 ± 0.08 a |
| 20:4ω-3 | 1.78 ± 0.07 b | 1.77 ± 0.00 b | 0.85 ± 0.06 a |
| 20:5ω-3 | 10.96 ± 0.03 b | 17.59 ± 0.59 c | 4.85 ± 0.45 a |
| 22:1ω-11 | 5.06 ± 0.18 b | 2.10 ± 0.06 a | 5.20 ± 0.17 b |
| 22:1ω-9 | 0.16 ± 0.04 a | 0.79 ± 0.00 b | 0.26 ± 0.05 a |
| 22:4ω-6 | 1.53 ± 0.09 b | 1.86 ± 0.03 c | 0.68 ± 0.13 a |
| 22:5ω-3 | 1.43 ± 0.12 a | 2.97 ± 0.20 b | 1.49 ± 0.01 a |
| 22:6ω-3 | 22.50 ± 0.45 b | 46.51 ± 0.34 c | 16.25 ± 0.14 a |
| SFA | 17.31 ± 1.51 b | 4.73 ± 0.03 a | 25.13 ± 0.20 c |
| MUFA | 25.16 ± 1.18 b | 8.51 ± 0.10 a | 36.26 ± 0.42 c |
| PUFA | 57.53 ± 1.35 b | 86.76 ± 0.07 c | 38.61 ± 0.22 a |
| Totω-3 | 45.14 ± 1.75 b | 77.17 ± 0.24 c | 28.44 ± 0.52 a |
| Totω-6 | 9.20 ± 0.86 c | 7.63 ± 0.20 b | 6.44 ± 0.87 a |
| EPA + DHA | 33.46 ± 1.02 b | 64.10 ± 0.25 c | 21.09 ± 0.31 a |
| PI | 3.63 ± 0.25 b | 28.81 ± 0.95 c | 1.47 ± 0.03 a |
| IA | 0.32 ± 0.02 b | 0.06 ± 0.00 a | 0.53 ± 0.02 c |
| IT | 0.11 ± 0.01 b | 0.02 ± 0.00 a | 0.23 ± 0.01 c |
| R | 1.89 ± 0.23 b | 13.95 ± 0.83 c | 0.73 ± 0.01 a |
| EPA Enrichment Factor | 1.00 ± 0.07 b | 1.54 ± 0.05 c | 0.90 ± 0.08 a |
| DHA Enrichment Factor | 1.00 ± 0.07 b | 1.99 ± 0.01 c | 0.69 ± 0.01 a |
| PUFA Enrichment Factor | 1.00 ± 0.07 b | 1.45 ± 0.02 c | 0.70 ± 0.01 a |
| PUFA/SFA | 3.32 ± 0.25 b | 18.35 ± 0.10 c | 1.54 ± 0.01 a |
Different superscript letters in the same row indicate significant differences p < 0.05). The data are reported as mean ± standard deviation, n = 12.
Figure 1Representative phase-contrast images at 40× magnification (scale bar = 100 μm). Untreated cells (Control), SAF-1 cell treated with enriched in PUFA (PUFA-SPe), and exhausted in fatty acid ethyl esters (PUFA-SPd).
Figure 2Relative expression of transcription factors (pparβ and pparγ), lipid metabolism-related genes (D6D and fas) and fatty acid transporters (cd36, fatp1, fabp1) in SAF-1 cell line treated or not (Control) with total FA ethyl esters (TFA), enriched in PUFA (PUFA-SPe), and exhausted in fatty acid ethyl esters (PUFA-SPd). Date are shown as mean ± SEM (n = 3). Different letters indicate significant differences among treatments (p < 0.05). Peroxisome proliferator-activated receptor β (pparβ), peroxisome proliferator-activated receptor γ (pparγ), Delta 6 desaturase (D6D), fatty acid synthase (fas), fat translocase/cluster of differentiation (cd36), fatty acid transporter protein 1 (fatp1) and fatty acid binding protein (fabp1).
S. aurata primer sequences used for real-time PCR.
| Gene | F/R Primer Sequence (5′–3′) |
|---|---|
|
| Fw CAGGTGACTTTGCTGAAGTA |
|
| Rv TAAAGGGCTTTCTTAAGCTG |
| Fw CTCAAGAGTCTCAGGAAACC | |
|
| Rv GATAATGACAGCCAGAAACA |
| Fw TACCTTCGCTACCTGTGCTG | |
|
| Rv TTGCAGGTGGTTGTAACTG |
| Fw TGCCATTGCCATAGCACTCA | |
|
| Rv ACCTTTGCCCTTTGTGTGGA |
| Fw GTCGTGGCTCAAGTCTTCCA | |
|
| Rv TTTCCCGTGGCCTGTATTCC |
| Fw CAACAGAGGTGGAGGGCATT | |
|
| Rv GGGGAGATACGCAGGAACAC |
| Fw CATGAAGGCGATTGGTCTCC | |
| Rv GTCTCCAAGTCTGCCTCCTT | |
|
| Fw TGTGCCGCTAGAGGTGAAATT |
| Rv GCAAATGCTTTCGCTTTCG |